newsfilter
← Latest News
GlobeNewswire·

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels observed in the OPTIC